110 related articles for article (PubMed ID: 21728981)
1. Anti-cancer peptides from ras-p21 and p53 proteins.
Pincus MR; Fenelus M; Sarafraz-Yazdi E; Adler V; Bowne W; Michl J
Curr Pharm Des; 2011; 17(25):2677-98. PubMed ID: 21728981
[TBL] [Abstract][Full Text] [Related]
2. Development of new anti-cancer peptides from conformational energy analysis of the oncogenic ras-p21 protein and its complexes with target proteins.
Pincus MR
Front Biosci; 2004 Sep; 9():3486-509. PubMed ID: 15353372
[TBL] [Abstract][Full Text] [Related]
3. Peptides designed from molecular modeling studies of the ras-p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth.
Kanovsky M; Michl J; Botzolaki G; Morin J; Kovac C; Chung DL; Chie L; Friedman FK; Pincus MR
Cancer Chemother Pharmacol; 2003 Sep; 52(3):202-8. PubMed ID: 12783204
[TBL] [Abstract][Full Text] [Related]
4. Two peptides derived from ras-p21 induce either phenotypic reversion or tumor cell necrosis of ras-transformed human cancer cells.
Adler V; Bowne W; Kamran I; Michl J; Friedman FK; Chin E; Zenilman M; Pincus MR
Cancer Chemother Pharmacol; 2008 Aug; 62(3):491-8. PubMed ID: 18066549
[TBL] [Abstract][Full Text] [Related]
5. Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer.
Bowne WB; Michl J; Bluth MH; Zenilman ME; Pincus MR
Cancer Ther; 2007; 5B():331-344. PubMed ID: 18007958
[TBL] [Abstract][Full Text] [Related]
6. Specificity of inhibition of ras-p21 signal transduction by peptides from GTPase activating protein (GAP) and the son-of sevenless (SOS) ras-specific guanine nucleotide exchange protein.
Chie L; Chung D; Pincus MR
Protein J; 2005 May; 24(4):253-8. PubMed ID: 16283548
[TBL] [Abstract][Full Text] [Related]
7. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.
Davitt K; Babcock BD; Fenelus M; Poon CK; Sarkar A; Trivigno V; Zolkind PA; Matthew SM; Grin'kina N; Orynbayeva Z; Shaikh MF; Adler V; Michl J; Sarafraz-Yazdi E; Pincus MR; Bowne WB
Ann Clin Lab Sci; 2014; 44(3):241-8. PubMed ID: 25117093
[TBL] [Abstract][Full Text] [Related]
8. A peptide from a ras effector-domain blocks ras-dependent cardiac hypertrophy in myocytes.
Deng L; Boujdir M; Tremontano A; Pincus MR; El-Sherif N
Ann Clin Lab Sci; 2009; 39(4):351-60. PubMed ID: 19880762
[TBL] [Abstract][Full Text] [Related]
9. A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti- ras peptide.
Way D; Smith S; Sivendran S; Chie L; Kanovsky M; Brandt-Rauf PW; Chung DL; Michl J; Pincus MR
Cancer Chemother Pharmacol; 2002 Jun; 49(6):429-37. PubMed ID: 12107546
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic and activated wild-type ras-p21 proteins induce different isoforms of protein kinase C in mitogenic signal transduction.
Chie L; Qu Y; Chung D; Boutjdir M; Pincus MR
J Protein Chem; 2003 Nov; 22(7-8):625-9. PubMed ID: 14714729
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ras-induced oocyte maturation by peptides from ras-p21 and GTPase activating protein (GAP) identified as being effector domains from molecular dynamics calculations.
Friedman FK; Chie L; Chung D; Robinson R; Brandt-Rauf P; Yamaizumi Z; Pincus MR
J Protein Chem; 2002 Jul; 21(5):361-6. PubMed ID: 12206510
[TBL] [Abstract][Full Text] [Related]
12. Peptides That Block RAS-p21 Protein-Induced Cell Transformation.
Pincus MR; Lin B; Patel P; Gabutan E; Zohar N; Bowne WB
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831007
[TBL] [Abstract][Full Text] [Related]
13. A peptide from the GAP-binding domain of the ras-p21 protein and azatyrosine block ras-induced maturation of Xenopus oocytes.
Chung DL; Brandt-Rauf P; Murphy RB; Nishimura S; Yamaizumi Z; Weinstein IB; Pincus MR
Anticancer Res; 1991; 11(4):1373-8. PubMed ID: 1746893
[TBL] [Abstract][Full Text] [Related]
14. Plasmid expression of a peptide that selectively blocks oncogenic ras-p21-induced oocyte maturation.
Kovac C; Clie L; Morin J; Friedman FK; Robinson R; Chung DL; Kanovsky M; Flom J; Brandt-Rauf PW; Yamaizumi Z; Michl J; Pincus MR
Cancer Chemother Pharmacol; 2001 Jul; 48(1):9-14. PubMed ID: 11488531
[TBL] [Abstract][Full Text] [Related]
15. Identification, using molecular dynamics, of an effector domain of the ras-binding domain of the raf-p74 protein that is uniquely involved in oncogenic ras-p21 signaling.
Chen JM; Rijhwani K; Friedman FK; Hyde MJ; Pincus MR
J Protein Chem; 2000 Oct; 19(7):545-51. PubMed ID: 11233167
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of oncogenic ras-p21 in vivo by agents that block its interaction with jun-N-kinase (JNK) and jun proteins. Implications for the design of selective chemotherapeutic agents.
Amar S; Glozman A; Chung D; Adler V; Ronai Z; Friedman FK; Robinson R; Brandt-Rauf P; Yamaizumi Z; Pincus MR
Cancer Chemother Pharmacol; 1997; 41(1):79-85. PubMed ID: 9443618
[TBL] [Abstract][Full Text] [Related]
17. The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells.
Bowne WB; Sookraj KA; Vishnevetsky M; Adler V; Sarafraz-Yazdi E; Lou S; Koenke J; Shteyler V; Ikram K; Harding M; Bluth MH; Ng M; Brandt-Rauf PW; Hannan R; Bradu S; Zenilman ME; Michl J; Pincus MR
Ann Surg Oncol; 2008 Dec; 15(12):3588-600. PubMed ID: 18931881
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation.
Lin AW; Lowe SW
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5025-30. PubMed ID: 11309506
[TBL] [Abstract][Full Text] [Related]
19. The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide.
Sookraj KA; Bowne WB; Adler V; Sarafraz-Yazdi E; Michl J; Pincus MR
Cancer Chemother Pharmacol; 2010 Jul; 66(2):325-31. PubMed ID: 20182728
[TBL] [Abstract][Full Text] [Related]
20. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.
Sarafraz-Yazdi E; Bowne WB; Adler V; Sookraj KA; Wu V; Shteyler V; Patel H; Oxbury W; Brandt-Rauf P; Zenilman ME; Michl J; Pincus MR
Proc Natl Acad Sci U S A; 2010 Feb; 107(5):1918-23. PubMed ID: 20080680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
